SYK Stock Forecast 2025-2026
Distance to SYK Price Targets
SYK Price Momentum
10 Quality Stocks Worth Considering Now
Researching Stryker (SYK) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SYK and similar high-potential opportunities.
Latest SYK Stock Price Targets & Analyst Predictions
Based on our analysis of 34 Wall Street analysts, SYK has a bullish consensus with a median price target of $435.00 (ranging from $306.00 to $465.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $367.77, the median forecast implies a 18.3% upside. This outlook is supported by 22 Buy, 9 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYK Analyst Ratings
SYK Price Target Range
Latest SYK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Needham | Mike Matson | Buy | Reiterates | $442.00 |
| Feb 26, 2025 | Citigroup | Joanne Wuensch | Buy | Reinstates | $450.00 |
| Feb 18, 2025 | JMP Securities | David Turkaly | Market Perform | Maintains | $0.00 |
| Feb 10, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $443.00 |
| Jan 30, 2025 | Goldman Sachs | David Roman | Neutral | Maintains | $427.00 |
| Jan 30, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $413.00 |
| Jan 29, 2025 | Stifel | Rick Wise | Buy | Maintains | $440.00 |
| Jan 29, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $435.00 |
| Jan 29, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $435.00 |
| Jan 29, 2025 | Needham | Mike Matson | Buy | Reiterates | $442.00 |
| Jan 29, 2025 | JP Morgan | Robbie Marcus | Overweight | Maintains | $445.00 |
| Jan 29, 2025 | Canaccord Genuity | Kyle Rose | Buy | Maintains | $435.00 |
| Jan 7, 2025 | Needham | Mike Matson | Buy | Reiterates | $442.00 |
| Jan 7, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $425.00 |
| Jan 7, 2025 | JMP Securities | David Turkaly | Market Perform | Reiterates | $0.00 |
| Dec 18, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $409.00 |
| Dec 12, 2024 | Needham | Mike Matson | Buy | Maintains | $442.00 |
| Dec 11, 2024 | RBC Capital | Shagun Singh | Outperform | Reiterates | $425.00 |
| Dec 11, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $427.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $450.00 |
Stryker Corporation (SYK) Competitors
The following stocks are similar to Stryker based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stryker Corporation (SYK) Financial Data
Stryker Corporation has a market capitalization of $140.37B with a P/E ratio of 47.4x. The company generates $22.60B in trailing twelve-month revenue with a 13.2% profit margin.
Revenue growth is +10.7% quarter-over-quarter, while maintaining an operating margin of +25.6% and return on equity of +15.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Stryker Corporation (SYK) Business Model
About Stryker Corporation
Provides innovative medical technology solutions.
Stryker Corporation generates revenue through the sale of medical devices and surgical equipment across various healthcare sectors, including orthopedics and neurotechnology. By focusing on research and development, the company continually enhances its product offerings, which helps maintain strong relationships with hospitals and healthcare providers.
Stryker's extensive distribution network and partnerships with medical professionals enable it to deliver advanced technologies that improve surgical precision and patient recovery worldwide. The company's commitment to innovation positions it as a leader in the medical technology industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
53,000
CEO
Mr. Kevin A. Lobo
Country
United States
IPO Year
1988
Website
www.stryker.comStryker Corporation (SYK) Latest News & Analysis
The Big 3: MMM, PM, SYK
9 days agoDan Deming highlights 3M (MMM), Philip Morris (PM), and Stryker (SYK) as "defensive" plays with upside potential amid ongoing market volatility.
Elevated market volatility makes defensive stocks like 3M, Philip Morris, and Stryker attractive for stability and potential upside, appealing to risk-averse investors seeking safer options.
Tariffs are impacting the Medical Device industry, but companies SYK, MDT, and PODD are expected to remain resilient amid rising trade tensions.
Rising tariffs could increase costs for many companies, but SYK, MDT, and PODD may benefit from competitive advantages, signaling potential resilience and investment opportunities in the sector.
Stryker (NYSE: SYK) showcased advancements in Mako SmartRobotics™ for various orthopedic procedures at the AAOS 2025 Annual Meeting, highlighting innovation in medical technology.
Stryker's advancements in Mako SmartRobotics™ highlight growth potential in medical tech, signaling increased market competitiveness and innovation, which can positively impact stock performance.
SYK launched the next-gen Mako SmartRobotics, enhancing precision in hip, knee, and spine surgeries, and introduces first-to-market robotic hip revision technology.
SYK's next-gen Mako SmartRobotics enhances surgical precision and introduces unique technology, potentially increasing market share and driving revenue growth in the orthopedic sector.
Inari Medical, now part of Stryker (NYSE: SYK), launched the Artix Thrombectomy System on March 6, 2025, enhancing its medical technology offerings.
Inari Medical's launch of the Artix Thrombectomy System under Stryker could enhance revenue streams and market competitiveness, signaling growth potential for investors in the medical technology sector.
Stryker has launched Steri-Shield 8, a new PPE system designed for improved fit, visibility, and protection, strengthening its position in the medical safety market.
Stryker's launch of Steri-Shield 8 enhances its competitive position and may drive revenue growth, positively impacting stock performance and investor confidence in the medical safety sector.
Frequently Asked Questions About SYK Stock
What is Stryker Corporation's (SYK) stock forecast for 2025?
Based on our analysis of 34 Wall Street analysts, Stryker Corporation (SYK) has a median price target of $435.00. The highest price target is $465.00 and the lowest is $306.00.
Is SYK stock a good investment in 2025?
According to current analyst ratings, SYK has 22 Buy ratings, 9 Hold ratings, and 1 Sell ratings. The stock is currently trading at $367.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYK stock?
Wall Street analysts predict SYK stock could reach $435.00 in the next 12 months. This represents a 18.3% increase from the current price of $367.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stryker Corporation's business model?
Stryker Corporation generates revenue through the sale of medical devices and surgical equipment across various healthcare sectors, including orthopedics and neurotechnology. By focusing on research and development, the company continually enhances its product offerings, which helps maintain strong relationships with hospitals and healthcare providers.
What is the highest forecasted price for SYK Stryker Corporation?
The highest price target for SYK is $465.00 from at , which represents a 26.4% increase from the current price of $367.77.
What is the lowest forecasted price for SYK Stryker Corporation?
The lowest price target for SYK is $306.00 from at , which represents a -16.8% decrease from the current price of $367.77.
What is the overall SYK consensus from analysts for Stryker Corporation?
The overall analyst consensus for SYK is bullish. Out of 34 Wall Street analysts, 22 rate it as Buy, 9 as Hold, and 1 as Sell, with a median price target of $435.00.
How accurate are SYK stock price projections?
Stock price projections, including those for Stryker Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
